Despite market fluctuations and cost pressures, Davipharm – a member of Adamed Group –  continues to strengthen its position as a leading local pharmaceutical manufacturer through strategic investments in R&D, technology transfer, and facility upgrades.

Over the next five years (2026–2030), Davipharm will invest over USD 20 million in R&D project to deliver high-quality products, accelerate the value of generic medicines including oncology drugs, and expand access to international markets; as well as to facilitate modernization and equipment upgrades to strengthen R&D capabilities and support innovation-driven growth.

The investment also focuses on upgrading R&D infrastructure for high-potent (HP) drug development, enhancing analytical capabilities, and integrating technologies to ensure product quality and global compliance.

Mr. Arunkumar Muthumalai – R&D Director of Davipharm, shared insights into the company’s long-term strategy: “Innovation remains at the core of our R&D strategy. Through formulation improvement, analytical excellence, and technology development, we are creating high-quality generic products that meet international standards while ensuring affordability and accessibility for patients in Vietnam and worldwide.”

Photo: Davipharm’s factory in Binh Duong (HCMC)

The investment covers facility renovation to ensure protection in high-potent drug formulation research and development, alongside CAPEX allocations for both analytical and formulation functions. These upgrades aim to ensure strict compliance with international quality standards while boosting efficiency in new product development.

Since Adamed’s first acquisition of 70% of Davipharm’s shares in 2017 and the full acquisition in 2023, the company has undergone a profound transformation. Davipharm stands among the largest Polish private investments in Vietnam and is one of the fastest-growing pharmaceutical firms in the country today.

From 2021, Davipharm has been among a select group of Vietnamese companies certified with EU-GMP for non-sterile products in capsules, hard-shells, and tablets. In 2024, Davipharm became the first company in Vietnam and the Southeast Asian region to obtain EU-GMP certification for its High Potent (HP) Zone dedicated to oncology drug production, a significant milestone that underlines its leadership in high-quality pharmaceutical manufacturing.

Photo: Inside Davipharm’s EU-GMP certified HP Zone

Vietnam combines rapid economic growth – estimated at 8% in 2025 according to the General Statistics Office, with ambitious plans to modernize its healthcare system under the National Strategy for the development of the pharmaceutical industry to 2030 – Vision to 2045. The country is being talked about as one of the fastest-growing markets in Asia and one of the key directions for the development of Adamed Group.

The company’s new developments based on the technology transfers meet the strict requirements of the highly regulated markets, allowing to produce high-quality medicines not only for Vietnamese patients but also for export to the countries with stringent regulatory authority.

Davipharm’s outlook to 2028 is ambitious, aiming to become a top pharmaceutical manufacturer in Vietnam and a Southeast Asia export hub. Each year, the company plan to develop 12 new SKUs and launch value-added medicines for Vietnamese patients and international markets.

Davipharm’s roadmap for regional expansion is firmly anchored in regulatory alignment and global certifications. Beyond EU-GMP, the Philippines FDA…, the company is actively working toward compliance with EAEU-GMP, and SFDA-GMP standards to enable broader market access across Asia, the Middle East, and Eastern Europe.

This focus on quality and regulatory excellence not only enhances the company’s competitiveness but also reinforces the reputation of “Made in Vietnam” medicines as safe, effective, and globally trusted.

As Vietnam’s healthcare landscape embraces digital transformation, Davipharm is leveraging data-driven insights, quality systems, and modern R&D equipment to accelerate product development. By integrating innovation into every stage, from laboratory research to commercial manufacturing, the company seeks to build a sustainable foundation for long-term growth.

With the mission to “respond to the key challenges of modern medicine”, Davipharm continues to demonstrate that investing in innovation and quality is not only a business strategy but a commitment to better health outcomes for patients in Vietnam and beyond.

Source: Thanh Nien